View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 18, 2022

Moderna eyes combined Covid-19, flu booster by 2023

Moderna CEO Stéphane Bancel also said an Omicron-specific Covid-19 vaccine will enter clinical development in a matter of weeks.

By Darcy Jimenez

Moderna is aiming to market a Covid-19 and influenza booster vaccine combo within the next two years, CEO Stéphane Bancel has said.

The single shot offering protection against Covid-19, flu, and the common respiratory virus RSV could be ready ahead of 2023’s winter infectious season, he announced.

“Our goal is to be able to have a single annual booster so that we don’t have compliance issues where people don’t want to get two-to-three shots a winter,” Bancel said, speaking at a World Economic Forum panel session on Monday (17 January).

The US-based company first shared plans to develop a single jab combining its Covid-19 booster with a flu shot back in September, during a presentation to investors.

At the time, Bancel said Moderna could be the first company to bring a “high efficacy, pan-respiratory annual booster” to market.

The CEO also told Monday’s panel that a Moderna Covid-19 vaccine candidate targeting the highly transmissible Omicron variant will enter clinical development in the coming weeks. He added that data on the Omicron-specific jab could be shared with regulators as soon as March.

While many countries are now rolling out third shots of coronavirus vaccines to boost populations’ immunity against Covid-19, Bancel commented earlier this month that a fourth jab could be needed this year as the efficacy of initial vaccinations and booster doses declines.

In December, Israel began administering second booster doses to its most vulnerable or high-risk populations. This week, a preliminary study conducted in the country suggested a fourth Covid-19 vaccine shot helps to boost antibodies but does not provide enough protection to prevent Omicron infections.

Covid-19 vaccines: our most read articles

Related Companies

Free Report

Reshape regional strategies to navigate global uncertainties

The COVID-19 crisis triggered one of the worst peacetime recessions globally. Even as several economies tread the path to recovery, the surge in COVID-19 cases and emergence of new variants, coupled with geopolitical tensions, will continue to cloud the global outlook.  The Global Risk report uses GlobalData’s proprietary Country Risk Index to determine the existing and future level of global risk by assessing over 50 key indicators, including:  
  • Macroeconomic 
  • Political 
  • Social
  • Technological 
  • Environmental 
  • Legal 
Use our Country Risk Index scores to help you understand future global risk and determine your business strategies, growth plans and investment portfolios. 
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy